SAN DIEGO (May 31, 2017) – 10xBio, LLC, a privately-held biotechnology company, announced today that it has been issued patent 9,351,945 from the U.S. Patent and Trademark Office. The patent broadly covers formulations of the company’s product being developed for dermatologic applications. The Company expects to initiate Phase 1b/2a testing in the first quarter of 2018.

John Dobak, M.D., the company’s Chairman commented, “This patent gives us a strong proprietary position for our novel formulation. We expect additional methods of use patents to be allowed in the near future.”

About 10xBio
We are a biotechnology company that focuses on new uses for existing therapies and technologies. This strategy allows us to build on existing safety profiles and leverage known mechanisms of action, resulting in a streamlined development and regulatory process. Our most advanced asset, 10XB101, is a pharmaceutical product that addresses unmet needs in dermatologic medicine.  For more information, visit us at www.10xBio.com.

Contact:
10xBio, LLC.
John Dobak, M.D.
Chariman
Info@10xbio.com